Cardiovascular pharmacogenetics in the SNP era

Area of Science:

• Pharmacology
• Genetics
• Cardiovascular Medicine

Background:

• Cardiovascular drugs significantly reduce cardiovascular events, but patient responses vary, with some experiencing side effects.
• The aging population and rising cardiovascular risk factors necessitate improved drug efficacy and safety.
• Genetic factors influence drug response, highlighting the potential of pharmacogenetics.

Purpose of the Study:

• To explore the role of pharmacogenetics in predicting cardiovascular drug responses.
• To identify genetic markers associated with favorable responses and adverse events to cardiovascular medications.
• To assess the feasibility of large-scale genetic studies for cardiovascular drug development.

Main Methods:

• Utilizing pharmacogenetics to study variability in drug responses attributed to hereditary factors.
• Analyzing associations between genetic markers, such as single nucleotide polymorphisms (SNPs) and haplotypes, and drug responses.
• Employing high-throughput genotyping and bioinformatics to analyze over 200,000 SNPs across the human genome.

Main Results:

• Accumulating evidence indicates genetic control over drug responses, with reported associations between specific genotypes and cardiovascular drug effects.
• Large-scale SNP analysis demonstrates feasibility, with potential to identify genetic predispositions to adverse drug reactions.
• Linkage disequilibrium across haplotype blocks can be detected, potentially reducing the number of SNPs needed for future genome-wide scans.

Conclusions:

• Pharmacogenetics offers a powerful approach to personalize cardiovascular medicine by identifying 'good' responders and those at risk for adverse events.
• Advancements in genotyping technologies enable comprehensive genome-wide association studies for drug response.
• This pharmacogenetic approach is expected to significantly impact the future development and prescription of cardiovascular drugs.